Celularity Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CELU research report →
Range $3 – $3
Price Chart
About the company
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases.
- CEO
- Robert Joseph Hariri
- IPO
- 2019
- Employees
- 115
- HQ
- Florham Park, NJ, US
Get TickerSpark's AI analysis on CELU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $22.20M
- P/E
- -0.21
- Fwd P/E
- 0.51
- PEG
- 0.01
- P/S
- 0.84
- P/B
- -0.52
- EV/EBITDA
- -0.73
- Div Yield
- 0.00%
- Gross Margin
- 76.04%
- Op Margin
- -230.92%
- Net Margin
- -345.44%
- ROE
- 411.46%
- ROIC
- -151.11%
Latest fiscal year · YoY change
- Revenue
- $26.55M-51.0%
- Gross Profit
- $20.19M-48.5%
- Op Income
- $-61,308,000
- Net Income
- $-91,800,000-58.6%
- EPS
- $-3.59-35.7%
- OCF Growth
- -107.1%
- FCF Growth
- -102.0%
- 52W High
- $4.01
- 52W Low
- $0.56
- 50D MA
- $0.72
- 200D MA
- $1.16
- Beta
- 0.54
- RSI (14)
- 57
- Avg Volume
- 107.36K
No earnings-call transcripts are available for CELU yet.
- Free Float
- 65.2%
- Shares Outstanding
- 28.95M
- Float Shares
- 18.87M
of shares held by institutions
38 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| C V Starr & Co Inc | 764.07K | 0 |
| Vanguard Group Inc | 676.65K | 0 |
| Vanguard Capital Management LLC | 621.11K | 0 |
| Geode Capital Management, LLC | 167.15K | ▼ 23.93K |
| Citadel Advisors LLC | 99.05K | ▲ 99.05K |
| Vanguard Fiduciary Trust Co | 79.87K | 0 |
| Blackrock, Inc. | 76.36K | ▼ 51.14K |
| State Street Corp | 57.83K | 0 |
| Hrt Financial LP | 56.59K | ▲ 43.81K |
| Northern Trust Corp | 44.16K | 0 |
| Biltmore Family Office, LLC | 35.00K | 0 |
| Hb Wealth Management, LLC | 31.91K | ▼ 8.50K |
Held by 18 ETFs
Biggest fund positions in CELU by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 19, 26 | Philip & Daniele Barach Family Trust | other | 1,204,819 |
| Jun 19, 26 | Philip & Daniele Barach Family Trust | other | 839,160 |
| Jun 19, 26 | Barach Philip Alan | other | 1,204,819 |
| Jun 19, 26 | Barach Philip Alan | other | 839,160 |
| Jun 19, 26 | Barach Daniele Wolf | other | 1,204,819 |
| Jun 19, 26 | Barach Daniele Wolf | other | 839,160 |
| Dec 19, 25 | Barach Philip Alan | other | 1,204,819 |
| Jun 19, 26 | Barach Philip Alan | other | 839,160 |
| Dec 19, 25 | Barach Daniele Wolf | other | 1,204,819 |
| Jun 19, 26 | Barach Daniele Wolf | other | 839,160 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CELU coverage
Recent articles, reports, and earnings notes.
No research on CELU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CELU report →Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
globenewswire.com · Jun 4
Celularity Releases CEO Letter to Shareholders
globenewswire.com · Jun 3
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
globenewswire.com · Jun 3
Celularity Receives Nasdaq Notice Regarding Form 10-Q
globenewswire.com · May 29
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
globenewswire.com · May 1
NEXGEL Appoints Ian Blackman as Chief Financial Officer
globenewswire.com · Apr 27
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
globenewswire.com · Apr 21
Celularity Announces Closing of Transaction with NexGel
globenewswire.com · Apr 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.